REPL
Company Description
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
Track Record
| Metric | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (313.94M) | (247.30M) | (215.79M) | (174.28M) | (118.04M) | (80.87M) | (52.62M) | (30.83M) | (19.70M) | (7.70M) |
| EPS | -3.38 | -3.07 | -3.24 | -2.99 | -2.26 | -1.75 | -1.54 | -1.33 | -0.64 | -0.36 |
| Free Cash Flow | (284.57M) | (198.94M) | (191.13M) | (130.32M) | (84.52M) | (63.78M) | (67.09M) | (27.98M) | (16.15M) | (7.32M) |
| FCF / Share | -3.07 | -2.47 | -2.87 | -2.24 | -1.62 | -1.38 | -1.96 | -1.21 | -0.52 | -0.34 |
| Operating CF | (280.34M) | (192.25M) | (185.47M) | (128.05M) | (82.18M) | (61.39M) | (60.55M) | (25.38M) | (16.01M) | (7.08M) |
| Total Assets | 332.39M | 551.33M | 487.72M | 646.59M | 461.19M | 543.10M | 234.10M | 154.33M | 65.15M | 22.82M |
| Total Debt | 111.59M | 76.17M | 75.87M | 60.76M | 32.84M | 33.28M | 41.79M | 6.56M | 0 | 0 |
| Cash & Equiv | 209.02M | 111.12M | 74.46M | 146.59M | 105.95M | 182.52M | 59.50M | 25.70M | 17.58M | 20.59M |
| Book Value | 166.16M | 415.84M | 374.51M | 555.29M | 411.23M | 498.73M | 183.72M | 137.86M | (28.07M) | (11.52M) |
| Return on Equity | -1.89 | -0.59 | -0.58 | -0.31 | -0.29 | -0.16 | -0.29 | -0.22 | N/A | N/A |
| Metric | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (73.22M) | (70.93M) | (83.10M) | (86.69M) | (74.13M) | (66.34M) | (53.05M) | (53.77M) | (55.08M) | (51.12M) | (60.04M) | (49.55M) |
| EPS | -0.76 | -0.77 | -0.90 | -0.95 | -0.96 | -0.79 | -0.68 | -0.78 | -0.90 | -0.77 | -0.90 | -0.75 |
| Free Cash Flow | (56.17M) | (66.09M) | (82.56M) | (79.76M) | (54.87M) | (52.51M) | (40.72M) | (50.84M) | (47.91M) | (48.84M) | (45.34M) | (49.04M) |
| FCF / Share | -0.61 | -0.72 | -0.90 | -0.87 | -0.68 | -0.63 | -0.52 | -0.73 | -0.78 | -0.73 | -0.68 | -0.74 |
| Operating CF | (56.16M) | (65.95M) | (81.21M) | (77.02M) | (53.73M) | (50.71M) | (38.64M) | (49.17M) | (46.17M) | (47.12M) | (43.59M) | (48.59M) |
| Total Assets | 332.39M | 333.59M | 389.45M | 469.51M | 551.33M | 603.63M | 498.20M | 534.97M | 487.72M | 532.93M | 562.40M | 603.89M |
| Total Debt | 111.59M | 76.35M | 76.32M | 76.33M | 76.17M | 76.04M | 76.12M | 75.95M | 75.87M | 75.81M | 60.74M | 60.84M |
| Cash & Equiv | 209.02M | 122.95M | 102.30M | 97.37M | 111.12M | 172.25M | 113.49M | 151.66M | 74.46M | 97.67M | 76.00M | 106.48M |
| Book Value | 166.16M | 210.54M | 263.34M | 336.71M | 415.84M | 482.37M | 381.46M | 426.45M | 374.51M | 421.54M | 465.17M | 514.03M |
| Return on Equity | -0.44 | -0.34 | -0.32 | -0.26 | -0.18 | -0.14 | -0.14 | -0.13 | -0.15 | -0.12 | -0.13 | -0.10 |
